49 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
to similarly situated executives with the first such review effective January 2025.
(b)Annual Bonus. Subject to the terms of the Executive Severance … a bonus following the end of each calendar year that ends during the Employment Period (“Annual Bonus”), subject to: (i) objective criteria set forth
8-K
5sr4ymqnqhwefmsudi6
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
3sxrqktq xpddlaub
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
987ee wu8
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
4bvi iznlc9p1bxg1
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
qjni7dkyx1j3a
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
o0wivqx5nk
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.1
0vdh6 hqc
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.01
7eeonqv2p 5pd6
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
6ib9kis
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am